{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"14"}],"units":"Participants"}],"description":"Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\<10 mm; Partial Response (PR), at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters; Overall Response (OR) = CR + PR","groups":[{"description":"TRC102 50 mg/day PO days 1-4; Pemetrex 500 mg/m\\^2 IV over 10 min day1; Cisplatin 60 mg/m\\^2 IV over 30-60 min day1","id":"OG000","title":"Arm A, Dose Level 1 - 50mg TRC102, 60mg/m^2 Cisplatin (Phase I)"},{"description":"TRC102 75 mg/day PO days 1-4; Pemetrex 500 mg/m\\^2 IV over 10 min day1; Cisplatin 60 mg/m\\^2 IV over 30-60 min day1","id":"OG001","title":"Arm A, Dose Level 2 - 75mg TRC102, 60mg/m^2 Cisplatin (Phase I)"},{"description":"TRC102 100 mg/day PO days 1-4; Pemetrex 500 mg/m\\^2 IV over 10 min day1; Cisplatin 60 mg/m\\^2 IV over 30-60 min day1","id":"OG002","title":"Arm A, Dose Level 3 - 100mg TRC102, 60mg/m^2 Cisplatin (Phase I)"},{"description":"TRC102 100 mg/day PO days 1-4; Pemetrex 500 mg/m\\^2 IV over 10 min day1; Cisplatin 75 mg/m\\^2 IV over 30-60 min day1","id":"OG003","title":"Arm A, Dose Level 4 - 100mg TRC102, 75mg/m^2 Cisplatin (Phase I)"},{"description":"TRC102 50 mg/day PO on days 1-4; Pemetrex 500mg/m\\^2 IV over 10 min day 1","id":"OG004","title":"Arm B, Dose Level 1 - 50mg TRC102 (Phase II)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Up to 8 weeks post-treatment","title":"Number of Subject With Overall Response","type":"PRIMARY","unitOfMeasure":"Participants"}